Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Risk of venous thromboembolism after total hip and knee replacement in older adults with comorbidity and co-occurring comorbidities in the Nationwide Inpatient Sample (2003-2006).

Kapoor A, Labonte AJ, Winter MR, Segal JB, Silliman RA, Katz JN, Losina E, Berlowitz D.

BMC Geriatr. 2010 Sep 17;10:63. doi: 10.1186/1471-2318-10-63.

2.

Venous thromboembolism after joint replacement in older male veterans with comorbidity.

Kapoor A, Chew P, Silliman RA, Hylek EM, Katz JN, Cabral H, Berlowitz D.

J Am Geriatr Soc. 2013 Apr;61(4):590-601. doi: 10.1111/jgs.12161. Epub 2013 Mar 21.

3.

Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.

Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

J Med Econ. 2011;14(3):324-34. doi: 10.3111/13696998.2011.578698. Epub 2011 Apr 20.

PMID:
21506632
4.

The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: a 15-year retrospective cohort study of routine clinical practice.

Pedersen AB, Mehnert F, Sorensen HT, Emmeluth C, Overgaard S, Johnsen SP.

Bone Joint J. 2014 Apr;96-B(4):479-85. doi: 10.1302/0301-620X.96B4.33209.

PMID:
24692614
5.

Effect of post-discharge venous thromboembolism on hospital quality comparisons following hip and knee arthroplasty.

Kester BS, Merkow RP, Ju MH, Peabody TD, Bentrem DJ, Ko CY, Bilimoria KY.

J Bone Joint Surg Am. 2014 Sep 3;96(17):1476-84. doi: 10.2106/JBJS.M.01248.

PMID:
25187587
6.

National Trends in Deep Vein Thrombosis following Total Knee and Total Hip Replacement in the United States.

Dua A, Desai SS, Lee CJ, Heller JA.

Ann Vasc Surg. 2017 Jan;38:310-314. doi: 10.1016/j.avsg.2016.05.110. Epub 2016 Aug 12.

PMID:
27531085
7.

Population-based epidemiology of postoperative venous thromboembolism in Taiwanese patients receiving hip or knee arthroplasty without pharmacological thromboprophylaxis.

Wu PK, Chen CF, Chung LH, Liu CL, Chen WM.

Thromb Res. 2014 May;133(5):719-24. doi: 10.1016/j.thromres.2014.01.039. Epub 2014 Feb 5.

PMID:
24593913
8.

Prolonged outpatient vitamin K antagonist use and risk of venous thromboembolism in patients undergoing total hip or knee replacement.

Lalmohamed A, Vestergaard P, Jansen PA, Grove EL, de Boer A, Leufkens HG, van Staa TP, de Vries F.

J Thromb Haemost. 2013 Apr;11(4):642-50. doi: 10.1111/jth.12158.

9.

Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement.

Selby R, Borah BJ, McDonald HP, Henk HJ, Crowther M, Wells PS.

Thromb Res. 2012 Aug;130(2):166-72. doi: 10.1016/j.thromres.2012.01.013. Epub 2012 Feb 23.

PMID:
22365491
10.

Risk factors and distribution of symptomatic venous thromboembolism in total hip and knee replacements: prospective study.

Markovic-Denic L, Zivkovic K, Lesic A, Bumbasirevic V, Dubljanin-Raspopovic E, Bumbasirevic M.

Int Orthop. 2012 Jun;36(6):1299-305. doi: 10.1007/s00264-011-1466-5. Epub 2012 Jan 4.

11.

Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.

Penning-van Beest FJ, Overbeek JA, Meijer WM, Woodruff K, Jackson J, van der Vis H, van der Linden P, Herings RM.

Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):972-8. doi: 10.1002/pds.2187. Epub 2011 Jul 11.

PMID:
21748826
12.

Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty: analysis from the RECORD trials.

Cohn DM, Hermanides J, DeVries JH, Kamphuisen PW, Kuhls S, Homering M, Hoekstra JB, Lensing AW, Büller HR.

Thromb Haemost. 2012 Feb;107(2):225-31. doi: 10.1160/TH11-07-0447. Epub 2011 Dec 21.

PMID:
22187097
13.

Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.

Duggan ST.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):57-72. doi: 10.2165/11208470-000000000-00000. Review.

PMID:
22272729
14.
15.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

16.

In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty.

Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

J Med Econ. 2012;15(4):644-53. doi: 10.3111/13696998.2012.669438. Epub 2012 Mar 12.

PMID:
22356512
17.

The Incidence and Economic Burden of In-Hospital Venous Thromboembolism in the United States.

Shahi A, Chen AF, Tan TL, Maltenfort MG, Kucukdurmaz F, Parvizi J.

J Arthroplasty. 2017 Apr;32(4):1063-1066. doi: 10.1016/j.arth.2016.10.020. Epub 2016 Oct 21.

PMID:
27866951
18.

Pharmacologic Prophylaxis for Venous Thromboembolism Among Patients With Total Joint Replacement: An Electronic Medical Records Study.

Rosenman M, Liu X, Phatak H, Qi R, Teal E, Nisi D, Liu LZ, Parr JA.

Am J Ther. 2016 Mar-Apr;23(2):e336-44. doi: 10.1097/01.mjt.0000433946.78535.84.

PMID:
26736015
19.

Clinical venous thromboembolism following joint surgery: effect of extended thromboprophylaxis on its annual frequency and postoperative pattern over 22 years.

Dahl OE, Gudmundsen TE, Pripp AH, Aanesen JJ.

Clin Appl Thromb Hemost. 2014 Mar;20(2):117-23. doi: 10.1177/1076029613499820. Epub 2013 Oct 10.

PMID:
24113492
20.

Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.

Schiff RL, Kahn SR, Shrier I, Strulovitch C, Hammouda W, Cohen E, Zukor D.

Chest. 2005 Nov;128(5):3364-71.

PMID:
16304285

Supplemental Content

Support Center